Loading patent…
AssigneesThe Trustees of Columbia University in the City of New York, Ramot at Tel-Aviv University Ltd., Kimron Veterinary Institute
InventorsW. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
Estimating the term…
The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.
An engineered nucleic acid expression construct capable of driving expression of heterologous genes, wherein said expression construct is not based upon Tilapia Lake Virus (TiLV), and wherein said expression construct comprises at least the following heterologous gene:
An engineered nucleic acid expression construct capable of driving expression of heterologous genes, wherein said expression construct is not based upon Tilapia Lake Virus (TiLV), and wherein said expression construct comprises at least the following heterologous gene:
Dependencies are inferred from the claim text.